Report overview
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
This report aims to provide a comprehensive presentation of the global market for Darbepoetin Alfa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Darbepoetin Alfa. This report contains market size and forecasts of Darbepoetin Alfa in global, including the following market information:
Global Darbepoetin Alfa Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Darbepoetin Alfa Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Darbepoetin Alfa companies in 2022 (%)
The global Darbepoetin Alfa market was valued at US$ 5046 million in 2022 and is projected to reach US$ 4172.3 million by 2029, at a CAGR of -2.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The classification of Darbepoetin Alfa includes Epogen, Procrit, Aranesp and others, and the proportion of Epogen in 2017 is about 45%.
Darbepoetin Alfa is widely used for Patients with Chronic Kidney Disease, Patients with Cancer others. The most proportion of Darbepoetin Alfa is used for the Patients with Chronic Kidney Disease, and the proportion in 2017 is 62%.
North America is the largest consumption place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 41%.
Market competition is not intense. Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Novartis and 3SBio etc. are the leaders of the industry, with about 87% market shares.
We surveyed the Darbepoetin Alfa manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Darbepoetin Alfa Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Darbepoetin Alfa Market Segment Percentages, by Type, 2022 (%)
Epogen
Procrit
Aranesp
Others
Global Darbepoetin Alfa Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Darbepoetin Alfa Market Segment Percentages, by Application, 2022 (%)
Patients with Chronic Kidney Disease
Patients with Cancer
Others
Global Darbepoetin Alfa Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Darbepoetin Alfa Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Darbepoetin Alfa revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Darbepoetin Alfa revenues share in global market, 2022 (%)
Key companies Darbepoetin Alfa sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Darbepoetin Alfa sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Novartis
3SBio
Outline of Major Chapters:
Chapter 1: Introduces the definition of Darbepoetin Alfa, market overview.
Chapter 2: Global Darbepoetin Alfa market size in revenue and volume.
Chapter 3: Detailed analysis of Darbepoetin Alfa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Darbepoetin Alfa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Darbepoetin Alfa capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
